Business Context and Reporting Period
Company: Synthetic Blood International, Inc. (Note: Metadata listed "Tenax Therapeutics," but the filing text identifies the registrant as Synthetic Blood International, Inc.)
Reporting Period: Quarterly period ended January 31, 2001 (Unaudited).
Status: Development Stage Company.
Operations: The company is in the pre-clinical trial stage for its products, focusing on research and development (R&D) with no commercial revenue. It recently relocated its corporate offices from Kettering, Ohio, to Costa Mesa, California.
Key Financial Metrics
| Metric | Three Months Ended Jan 31, 2001 | Nine Months Ended Jan 31, 2001 | Balance Sheet (Jan 31, 2001) |
|---|---|---|---|
| Revenue | $0 | $0 | N/A |
| Net Loss | $(406,950) | $(1,169,084) | Accumulated Deficit: $(12,482,422) |
| Operating Expenses | $491,954 | $1,436,355 | N/A |
| Cash and Equivalents | N/A | N/A | $4,693,913 |
| Working Capital | N/A | N/A | $4,499,087 |
| Current Liabilities | N/A | N/A | $295,241 |
| Shares Outstanding | N/A | N/A | 88,244,436 |
Material Changes vs. Prior Period
- Expense Growth: Total expenses for the three months ended Jan 31, 2001, increased by $310,044 compared to the prior year period. R&D expenses rose from $69,764 to $234,760, and General and Administrative (G&A) expenses rose from $109,330 to $257,194.
- Drivers of Increase: The increase in R&D is attributed to the addition of a California laboratory, increased contract employees, and higher rent. G&A increases were driven by higher payroll, consulting fees, office expenses, and $33,000 in investor expenses related to a proxy statement.
- Net Loss: Net loss for the three-month period increased by $225,278 to $406,950. This increase was partially offset by a rise in "Other Income" (interest income) of $84,766 due to higher cash balances.
- Cash Flow: Net cash used in operating activities for the nine-month period was $1,096,158, compared to $589,496 in the prior year. Net cash provided by financing activities was $535,060, primarily from the sale of common stock.
Outlook, Risks, and Management Commentary
- Liquidity: Management believes current cash reserves ($4.69 million) are sufficient to meet liquidity needs for the next 18 months. Excess working capital is invested in short-term money market instruments.
- Capital Requirements: Significant additional financing is required for further development, testing, and potential FDA clinical trials. The company is actively pursuing private/institutional financing and strategic alliances but has no firm commitments as of Jan 31, 2001.
- Risks: Key risks include the inability to achieve positive pre-clinical results, failure to obtain FDA approval, inability to secure necessary financing, patent uncertainties, and potential dilution of existing shareholders if equity is issued to raise capital.
- Unusual Items: The company incurred $33,000 in investor expenses for a proxy statement during the quarter. It also recognized significant non-cash expenses related to stock options and issuance of stock for services.
Investor Verification Checklist
- Runway Validation: Verify if the projected 18-month cash runway remains accurate given the accelerated burn rate (operating cash burn of ~$1.1M for nine months).
- Financing Status: Confirm if any strategic partnerships or financing commitments have been secured since the filing date to fund the transition from pre-clinical to clinical trials.
- Dilution Impact: Assess the potential dilution to existing shareholders given the company's reliance on equity issuance (88.2M shares outstanding) to fund operations.
- Regulatory Milestones: Monitor progress on pre-clinical studies required to request FDA approval for clinical trials, as failure here would halt product development.
- Expense Management: Review the sustainability of the increased G&A and R&D spending, particularly the $33,000 investor expense and new California laboratory costs.